RecruitingPhase 2NCT06632600

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

Studying American trypanosomiasis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Intervention: LXE408(drug)
Enrollment: 130 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2025 – 2030

Study locations (17)

Olive View UCLA Educ and Res Ins, Sylmar, California, United States
University of Florida Shands, Gainesville, Florida, United States
Boston Medical Center, Boston, Massachusetts, United States
Baylor College of Medicine, Houston, Texas, United States
Novartis Investigative Site, CABA, Buenos Aires, Argentina
Novartis Investigative Site, Corrientes, Argentina
Novartis Investigative Site, Córdoba, Argentina
Novartis Investigative Site, Formosa, Argentina
Novartis Investigative Site, Montes Claros, Minas Gerais, Brazil
Novartis Investigative Site, Recife, Pernambuco, Brazil
Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site, São Caetano do Sul, São Paulo, Brazil
Novartis Investigative Site, Barranquilla, Atlántico, Colombia
Novartis Investigative Site, Yopal, Casanare Department, Colombia
Novartis Investigative Site, Bogotá, Colombia
+2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06632600 on ClinicalTrials.gov

Other trials for American trypanosomiasis

Additional recruiting or active studies for the same condition.

See all trials for American trypanosomiasis →

← Back to all trials